{"pmid":32424591,"title":"COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link?","text":["COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link?","Cell Stress Chaperones","De Maio, Antonio","Hightower, Lawrence E","32424591"],"journal":"Cell Stress Chaperones","authors":["De Maio, Antonio","Hightower, Lawrence E"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32424591","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s12192-020-01121-0","topics":["Treatment"],"weight":1,"_version_":1667252837699026944,"score":9.490897,"similar":[{"pmid":32442317,"title":"The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).","text":["The case for Chronotherapy in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS).","COVID-19, the disease resulting from infection by a novel coronavirus: SARS-Cov2 that has rapidly spread since November 2019 leading to a global pandemic. SARS-Cov2 has infected over 4 million people and caused over 290,000 deaths worldwide. Although most cases are mild, a subset of patients develop a severe and atypical presentation of Acute Respiratory Distress Syndrome (ARDS) that is characterised by a cytokine release storm (CRS). Paradoxically, treatment with anti-inflammatory agents and immune regulators has been associated with worsening of ARDS. We hypothesize that the intrinsic circadian clock of the lung and the immune system may regulate individual components of CRS and thus chronotherapy may be used to effectively manage ARDS in COVID-19 patients.","Br J Pharmacol","Tamimi, Faleh","Abusamak, Mohammad","Akkanti, Bindu","Chen, Zheng","Yoo, Seung-Hee","Karmouty-Quintana, Harry","32442317"],"abstract":["COVID-19, the disease resulting from infection by a novel coronavirus: SARS-Cov2 that has rapidly spread since November 2019 leading to a global pandemic. SARS-Cov2 has infected over 4 million people and caused over 290,000 deaths worldwide. Although most cases are mild, a subset of patients develop a severe and atypical presentation of Acute Respiratory Distress Syndrome (ARDS) that is characterised by a cytokine release storm (CRS). Paradoxically, treatment with anti-inflammatory agents and immune regulators has been associated with worsening of ARDS. We hypothesize that the intrinsic circadian clock of the lung and the immune system may regulate individual components of CRS and thus chronotherapy may be used to effectively manage ARDS in COVID-19 patients."],"journal":"Br J Pharmacol","authors":["Tamimi, Faleh","Abusamak, Mohammad","Akkanti, Bindu","Chen, Zheng","Yoo, Seung-Hee","Karmouty-Quintana, Harry"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442317","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/bph.15140","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119453257728,"score":54.20279},{"pmid":32471203,"title":"Proactive COVID-19 Infection Prevention Measures in a Hyperbaric Oxygen Therapy Center.","text":["Proactive COVID-19 Infection Prevention Measures in a Hyperbaric Oxygen Therapy Center.","Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China in December 2019 and its subsequent global spread, Taiwan has been combatting this pandemic. COVID-19 is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As SARS-CoV-2 can be transmitted through droplets and aerosols, we cannot ignore the risk of transmission during hyperbaric oxygen therapy (HBOT). Our hyperbaric oxygen therapy center prioritizes preventing the spread of COVID-19 and maintaining operation for the patients during the pandemic. The aim of this article is to share the protocol that we have adopted in our hyperbaric oxygen therapy center to help prevent the spread of COVID-19.","Medicina (Kaunas)","Lo, Jing-Jou","Wang, Su-Chen","Lee, Hsiu-Ying","Lee, Su-Shin","Lee, Hsiao-Chen","Hung, Ching-Tzu","Huang, Shu-Hung","32471203"],"abstract":["Since the outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China in December 2019 and its subsequent global spread, Taiwan has been combatting this pandemic. COVID-19 is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As SARS-CoV-2 can be transmitted through droplets and aerosols, we cannot ignore the risk of transmission during hyperbaric oxygen therapy (HBOT). Our hyperbaric oxygen therapy center prioritizes preventing the spread of COVID-19 and maintaining operation for the patients during the pandemic. The aim of this article is to share the protocol that we have adopted in our hyperbaric oxygen therapy center to help prevent the spread of COVID-19."],"journal":"Medicina (Kaunas)","authors":["Lo, Jing-Jou","Wang, Su-Chen","Lee, Hsiu-Ying","Lee, Su-Shin","Lee, Hsiao-Chen","Hung, Ching-Tzu","Huang, Shu-Hung"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471203","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/medicina56060261","keywords":["hbot","sars-cov-2","coronavirus disease 2019","cross infection","infection control"],"locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention"],"weight":1,"_version_":1668255193266913280,"score":52.271545},{"pmid":32405693,"title":"Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?","text":["Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)?","Ann Hematol","Caocci, Giovanni","La Nasa, Giorgio","32405693"],"journal":"Ann Hematol","authors":["Caocci, Giovanni","La Nasa, Giorgio"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405693","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s00277-020-04067-6","e_drugs":["INCB018424"],"topics":["Treatment"],"weight":1,"_version_":1666802845373956097,"score":50.04856},{"pmid":32437820,"title":"Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS).","text":["Low dose radiation therapy as a potential life saving treatment for COVID-19-induced acute respiratory distress syndrome (ARDS).","The new coronavirus COVID-19 disease caused by SARS-CoV-2 was declared a global public health emergency by WHO on Jan 30, 2020. Despite massive efforts from various governmental, health and medical organizations, the disease continues to spread globally with increasing fatality rates. Several experimental drugs have been approved by FDA with unknown efficacy and potential adverse effects. The exponentially spreading pandemic of COVID-19 deserves prime public health attention to evaluate yet unexplored arenas of management. We opine that one of these treatment options is low dose radiation therapy for severe and most critical cases. There is evidence in literature that low dose radiation induces an anti-inflammatory phenotype that can potentially afford therapeutic benefit against COVID-19-related complications that are associated with significant morbidity and mortality. Herein, we review the effects and putative mechanisms of low dose radiation that may be viable, useful and of value in counter-acting the acute inflammatory state induced by critical stage COVID-19.","Radiother Oncol","Dhawan, Gaurav","Kapoor, Rachna","Dhawan, Rajiv","Singh, Ravinder","Monga, Bharat","Giordano, James","Calabrese, Edward J","32437820"],"abstract":["The new coronavirus COVID-19 disease caused by SARS-CoV-2 was declared a global public health emergency by WHO on Jan 30, 2020. Despite massive efforts from various governmental, health and medical organizations, the disease continues to spread globally with increasing fatality rates. Several experimental drugs have been approved by FDA with unknown efficacy and potential adverse effects. The exponentially spreading pandemic of COVID-19 deserves prime public health attention to evaluate yet unexplored arenas of management. We opine that one of these treatment options is low dose radiation therapy for severe and most critical cases. There is evidence in literature that low dose radiation induces an anti-inflammatory phenotype that can potentially afford therapeutic benefit against COVID-19-related complications that are associated with significant morbidity and mortality. Herein, we review the effects and putative mechanisms of low dose radiation that may be viable, useful and of value in counter-acting the acute inflammatory state induced by critical stage COVID-19."],"journal":"Radiother Oncol","authors":["Dhawan, Gaurav","Kapoor, Rachna","Dhawan, Rajiv","Singh, Ravinder","Monga, Bharat","Giordano, James","Calabrese, Edward J"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437820","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.radonc.2020.05.002","keywords":["acute respiratory distress syndrome (ards)","anti-inflammatory phenotype","covid-19","cytokine storm","hormesis","low dose radiotherapy"],"topics":["Treatment"],"weight":1,"_version_":1667521393645846529,"score":49.597923},{"pmid":32279018,"pmcid":"PMC7118619","title":"Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports.","text":["Poor survival with extracorporeal membrane oxygenation in acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19): Pooled analysis of early reports.","J Crit Care","Henry, Brandon Michael","Lippi, Giuseppe","32279018"],"journal":"J Crit Care","authors":["Henry, Brandon Michael","Lippi, Giuseppe"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32279018","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jcrc.2020.03.011","keywords":["acute respiratory distress syndrome","covid-19","coronavirus","extracorporeal life support"],"topics":["Treatment"],"weight":1,"_version_":1666138491570880513,"score":48.699314}]}